CABIO BIOTECH (WUHAN) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.97 CNY | +0.82% |
|
-6.50% | -10.78% |
| 04-30 | Mainland China stocks edge lower ahead of long Labor Day holiday, Hong Kong rises | RE |
| 04-26 | Cabio Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4,752 | 7,373 | 5,438 | 3,013 | 2,688 | - | - |
| Enterprise Value (EV) 1 | 4,752 | 7,373 | 5,438 | 3,013 | 2,688 | 2,688 | 2,688 |
| P/E ratio | 36.3 x | 57.4 x | 83.9 x | 33.1 x | 22.9 x | 17.9 x | 15.1 x |
| Yield | - | 0.54% | 0.66% | 1.12% | 1.69% | 0.97% | - |
| Capitalization / Revenue | - | 21 x | 12.5 x | 6.76 x | 5.03 x | 3.95 x | 3.78 x |
| EV / Revenue | - | 21 x | 12.5 x | 6.76 x | 5.03 x | 3.95 x | 3.78 x |
| EV / EBITDA | - | 51.5 x | 70 x | 23.1 x | 14.7 x | 11.8 x | 8.87 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | 5.34 x | 3.83 x | 2.04 x | 1.71 x | 1.59 x | 1.51 x |
| Nbr of stocks (in thousands) | 168,000 | 168,000 | 168,000 | 168,309 | 168,309 | - | - |
| Reference price 2 | 28.29 | 43.89 | 32.37 | 17.90 | 15.97 | 15.97 | 15.97 |
| Announcement Date | 21-02-21 | 22-02-27 | 23-02-27 | 24-02-23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 351.1 | 433.4 | 445.5 | 534.8 | 680 | 711 |
| EBITDA 1 | - | 143.2 | 77.7 | 130.4 | 183 | 227.2 | 303 |
| EBIT 1 | - | 117.2 | 51.09 | 82.33 | 112.5 | 153.2 | 196 |
| Operating Margin | - | 33.37% | 11.79% | 18.48% | 21.04% | 22.53% | 27.57% |
| Earnings before Tax (EBT) 1 | - | 152.1 | 78.14 | 101.4 | 128.2 | 166.8 | 196 |
| Net income 1 | 130.7 | 128.6 | 64.37 | 91.52 | 117 | 149.4 | 179 |
| Net margin | - | 36.62% | 14.85% | 20.54% | 21.88% | 21.97% | 25.18% |
| EPS 2 | 0.7786 | 0.7643 | 0.3857 | 0.5400 | 0.6967 | 0.8900 | 1.060 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | 0.2357 | 0.2143 | 0.2000 | 0.2700 | 0.1550 | - |
| Announcement Date | 21-02-21 | 22-02-27 | 23-02-27 | 24-02-23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 |
|---|---|---|
| Net sales 1 | - | 160.2 |
| EBITDA | - | - |
| EBIT 1 | - | -20.02 |
| Operating Margin | - | -12.5% |
| Earnings before Tax (EBT) 1 | - | -9.697 |
| Net income 1 | 27.84 | -13.49 |
| Net margin | - | -8.42% |
| EPS | 0.1643 | - |
| Dividend per Share | - | - |
| Announcement Date | 22-10-24 | 23-02-27 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 9.53% | 4.61% | 6.22% | 7.52% | 8.87% | 10% |
| ROA (Net income/ Total Assets) | - | 9.08% | 4.21% | - | 6.87% | 7.87% | 9.1% |
| Assets 1 | - | 1,416 | 1,530 | - | 1,704 | 1,899 | 1,967 |
| Book Value Per Share 2 | - | 8.220 | 8.450 | 8.770 | 9.320 | 10.00 | 10.60 |
| Cash Flow per Share 2 | - | 0.6100 | 1.050 | 0.4100 | 0.6200 | 0.5800 | - |
| Capex 1 | - | 173 | 249 | 297 | 164 | 127 | 115 |
| Capex / Sales | - | 49.34% | 57.52% | 66.76% | 30.57% | 18.73% | 16.17% |
| Announcement Date | 21-02-21 | 22-02-27 | 23-02-27 | 24-02-23 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
15.97
CNY
Average target price
18.5
CNY
Spread / Average Target
+15.84%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.78% | 368M | |
| +15.21% | 8.2B | |
| +5.29% | 7.61B | |
| +0.73% | 5.95B | |
| -6.04% | 3.72B | |
| -9.63% | 3.57B | |
| -5.76% | 1.27B | |
| -29.55% | 1.07B | |
| +15.23% | 988M | |
| -17.59% | 789M |
- Stock Market
- Equities
- 688089 Stock
- Financials Cabio Biotech (Wuhan) Co., Ltd.
